Replies to post #8132 on OncoSec Medical Inc (ONCSQ)

[lasers]

Some cancer tumors are more refractory than others. A combination of Electroporation plus IL-12 plus anti-PD-1 is expected to increase the tumor destruction percentage as well as produce more advanced NK cells for local and systemic responses.

Any of three Majors are possibility partners.

For itself OncoSec has stated as a 2014 milestone is initiation of a 4th solid tumor treatment.

[lasers]

For OncoSec shareholders wanting to read more on anti-PD-1 this video by BMS will be helpful.

https://bmsdm.secure.force.com/pd1pathway/index?TC=2009097&utm_source=google&utm_medium=cpc&utm_campaign=awareness&utm_term=pd1&utm_content=pdiopd1_textad_Home_text_tc2009097